Investors
Investors
Corporate Profile
We are a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program AKR-001 to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.
Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.